Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.35 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15067955 | 0.83 | MAPT (0.44) | CA1CA2CA7CA13ALDH1A1 | |
| SCHEMBL15067956 | 0.83 | MAPT (0.44) | CA1CA2CA7CA13ALDH1A1 | |
| SCHEMBL17517329 | 0.83 | MEN1 (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16475125 | 0.82 | KDM4E (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL20764944 | 0.82 | CA1 (0.39) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16047700 | 0.80 | GRIN2D (0.38) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL16914166 | 0.79 | POLB (0.34) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL23647925 | 0.79 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL30600835 | 0.79 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8884170 | 0.79 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119684283-A | Pyrrolo [2,3-c ] pyridines and use thereof | 山东新时代药业有限公司 | 2025-03-25 | — | — | CN | claimed |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | SAINT LOUIS UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4739307-A2 | TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY | The General Hospital Corporation (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260092065-A1 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | INCYTE CORP (US) | 2026-04-02 | — | — | US | disclosed |
| US-12459943-B2 | Crystalline solid forms of a BET inhibitor | INCYTE CORPORATION (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4637754-A2 | SELECTIVE BET INHIBITORS AND USES THEREOF | Tay Therapeutics Limited (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | Tay Therapeutics Limited (GB) | 2025-08-12 | — | — | US | disclosed |
| CN-120040445-A | Heterocyclopyridine-7-one compound and medical application thereof | 浙江大学金华研究院 | 2025-05-27 | — | — | CN | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| US-7820820-B2 | Method of preparation of azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100076191-A1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-25 | — | — | US | disclosed |
| US-20090312549-A1 | METHOD OF PREPARATION OF AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7601715-B2 | Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7598380-B2 | Method of preparation of azaindole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| WO-2007002308-A9 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL MYERS SQUIBB CO (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007019126-A2 | METHOD OF PREPARATION OF AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032503-A1 | Method of preparation of azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2007-02-08 | — | — | US | disclosed |
| US-20070032503-A1 | Method of preparation of azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2007-02-08 | — | — | US | disclosed |
| WO-2007002308-A2 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312549-A1 | METHOD OF PREPARATION OF AZAINDOLE DERIVATIVES | TPMT, HAVCR2, CYP3A43 | GRIN2D 501/4885GRIN3B 444/4885GRIN1 538/4885 |
| US-20070032503-A1 | Method of preparation of azaindole derivatives | TPMT, HAVCR2, CYP3A43 | GRIN2D 501/4885GRIN3B 444/4885GRIN1 538/4885 |
| US-12459943-B2 | Crystalline solid forms of a BET inhibitor | BRD1, BRD3, BRD2 | GRIN2D 1928/4885GRIN3B 3064/4885GRIN1 3300/4885 |
| US-20260092065-A1 | CRYSTALLINE SOLID FORMS OF A BET INHIBITOR | BRD2, BRDT, BRD1 | GRIN2D 823/4885GRIN3B 2221/4885GRIN1 2080/4885 |
| US-20100076191-A1 | PROCESS FOR PREPARING TRIAZOLE SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES AND NOVEL SALT FORMS PRODUCED THEREIN | NAT1, NISCH, AZI2 | GRIN2D 687/4885GRIN3B 1989/4885GRIN1 239/4885 |
| US-12636290-B2 | BET inhibitors for modulating DUX4 expression in FSHD | BRDT, BET1, PHKB | GRIN2D 4379/4885GRIN3B 4647/4885GRIN1 3915/4885 |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | TPMT, IL5, P2RY6 | GRIN2D 1599/4885GRIN3B 932/4885GRIN1 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.